TAS::75 0849::TAS SBIR TOPIC 255 PHASE II DEVELOPMENT OF ANTICANCER AGENTS

TAS::75 0849::TAS SBIR 主题 255 抗癌药物的第二阶段开发

• 批准号: 8342467
• 负责人: CATHERINE BURKHART
• 金额: $ 149.68万
• 依托单位: BUFFALO BIOLABS, LLC
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-30 至 2013-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8342467
• 关键词: Antineoplastic Agents; Biological Markers; Clinical; Contracts; Development; Drug Delivery Systems; Evaluation; Glioblastoma; Growth; Heat-Shock Response; Malignant Neoplasms; Malignant neoplasm of prostate; Maximum Tolerated Dose; Modeling; Mutation; Non-Small-Cell Lung Carcinoma; Normal tissue morphology; Outcome; Pathway interactions; Pharmaceutical Preparations; Phase; Primary carcinoma of the liver cells; Regimen; Renal Cell Carcinoma; Safety; Small Business Innovation Research Grant; Testing; Time; Toxic effect; Treatment Protocols; biological adaptation to stress; cancer type; improved; protein function; response; standard of care; tumor; tumor growth

Aberrant functioning of proteins within stress response pathways (e.g. p53, NF-B, heat shock response) are prominent features in many cancer types. Such alterations have been associated with poor response of tumors to conventional antitumor treatments. This is true for such cancers as non-small cell lung cancer, hepatocellular carcinoma, advanced prostate cancer, renal cell carcinoma and glioblastoma multiforme. Targeted therapies against these alterations may restore tumor response to treatment and, thus, improve clinical outcome. Multifunctional agents, such as the Curaxin to be studied in the context of this contract, have the potential to be more effective than drugs that target single pathways since they decrease the likelihood of tumors finding ways to circumvent their effects unlike single function agents where one mutation or inactivation of a component of the targeted pathway would make tumors less sensitive to treatment.

应激反应途径中蛋白质的异常功能（例如p53，NF-B，热休克反应）是许多癌症类型的突出特征。这种改变与肿瘤对常规抗肿瘤治疗的不良反应有关。对于非小细胞肺癌、肝细胞癌、晚期前列腺癌、肾细胞癌和多形性胶质母细胞瘤等癌症，情况也是如此。针对这些改变的靶向治疗可以恢复肿瘤对治疗的反应，从而改善临床结果。多功能药物，如Curaxin，有可能比靶向单一途径的药物更有效，因为它们降低了肿瘤找到规避其作用的方法的可能性，而不像单一功能药物，其中靶向途径的一个组分的突变或失活会使肿瘤对治疗不那么敏感。